- Home
- TTOO vs CGTX Comparison
TTOO vs CGTX Comparison
Compare TTOO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTOO
- CGTX
- Stock Information
- Founded
- TTOO 2006
- CGTX 2007
- Country
- TTOO United States
- CGTX United States
- Employees
- TTOO N/A
- CGTX N/A
- Industry
- TTOO Medical/Dental Instruments
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- TTOO Health Care
- CGTX Health Care
- Exchange
- TTOO Nasdaq
- CGTX Nasdaq
- Market Cap
- TTOO 36.4M
- CGTX 79.3M
- IPO Year
- TTOO 2014
- CGTX 2021
- Fundamental
- Price
- TTOO $0.97
- CGTX $0.54
- Analyst Decision
- TTOO Hold
- CGTX Buy
- Analyst Count
- TTOO 1
- CGTX 6
- Target Price
- TTOO $5.00
- CGTX $8.00
- AVG Volume (30 Days)
- TTOO 710.5K
- CGTX 588.8K
- Earning Date
- TTOO 11-13-2024
- CGTX 11-08-2024
- Dividend Yield
- TTOO N/A
- CGTX N/A
- EPS Growth
- TTOO N/A
- CGTX N/A
- EPS
- TTOO N/A
- CGTX N/A
- Revenue
- TTOO $7,164,000.00
- CGTX N/A
- Revenue This Year
- TTOO $50.31
- CGTX N/A
- Revenue Next Year
- TTOO $117.92
- CGTX N/A
- P/E Ratio
- TTOO N/A
- CGTX N/A
- Revenue Growth
- TTOO N/A
- CGTX N/A
- 52 Week Low
- TTOO $0.90
- CGTX $0.34
- 52 Week High
- TTOO $8.38
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- TTOO 18.34
- CGTX 54.28
- Support Level
- TTOO $0.90
- CGTX $0.50
- Resistance Level
- TTOO $1.86
- CGTX $0.64
- Average True Range (ATR)
- TTOO 0.15
- CGTX 0.07
- MACD
- TTOO -0.00
- CGTX 0.02
- Stochastic Oscillator
- TTOO 5.72
- CGTX 67.74
About TTOO T2 Biosystems Inc.
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.